Hopkins Dome.gif (1144 bytes)

Back to
Hopkins
Pancreas
Home

 

 

 

 

 

Oncology Center Building2.JPG (30660 bytes)      ribbon.JPG (1814 bytes)

The Genetics of Pancreatic Cancer

--The Discoveries

 

The People

Bibliography

You
Can Help!



 

 

Cell cycle.JPG (368235 bytes)

Mutations and the
Cell Cycle


 

alleles1.gif (9810 bytes)

Allelotype of Pancreatic
Cancer

 

Cell Line Mutation
Profiles

K-Ras Gene

p53 Gene

p16 Gene

DPC4 Gene

MKK4 Gene

TGF-beta and activin
Receptors

BRCA2 Gene

LKB1/STK11 Gene

Telomeric and Mitochondrial DNA

Various Chromosomes

 

 

13p.jpg (32632 bytes)

FISH picture


Technical section:
RDA Protocol

SAGE Results

DPC4 Primers

BRCA2 Primers

ALK5 Primers

Allelotype Markers

 

Helix8b.JPG (6139 bytes)

The laboratory has defined the frequency and positions of deletions of chromosomal material, and discovered highly frequent mutational changes affecting the DPC4 gene, p16 gene, and p53 gene. K-ras gene mutations are known to be common in pancreatic cancer. Mutant K-ras genes were present in the stool samples of patients with either pancreatic cancer or the precursor lesions for the cancer. A genetic link with familial breast cancer was discovered. Their work has suggested a model for the biology of pancreatic cancer, shown at left in the Mutations and the Cell Cycle link.



So, what does an individual pancreatic cancer look like when we view it with the lenses provided by the molecular genetic technology? Basically, it's a genetic mess. But it's a mess with underlying patterns, which they are now beginning to unravel. You can visualize the patterns through a brief tour of the Allelotype or of the Cell Line Mutation Profiles in the links to the left. Or review the roles of individual genes and chromosomes in pancreatic cancer through their links.



Pancreatic cancer was shown to be distinctively different from another well-studied gastrointestinal cancer type, colon cancer. APC gene mutations, seen in most colon neoplasms, are not found in pancreatic cancer. Also, a DNA mismatch repair defect, seen in 15% of colorectal cancer, is uncommon in pancreatic cancer. This research group therefore does not see pancreatic cancer as being modeled after any other cancer type. It is its own, very characteristic, entity. The aggressiveness of the disease exceeds that of most other carcinomas. Chemotherapeutic agents which may be active against other malignancies do not work effectively when used for pancreatic cancer. The laboratory therefore pursues a focused attempt to study pancreatic cancer as comprehensively and efficiently as can be achieved.